Syngene Intl.

Who are the top shareholders of the Syngene Intl.?

The top shareholders of Syngene International are Biocon Limited with 52.46%, mutual funds at 17.86%, and foreign institutional investors holding 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund with a 5.13% stake, while individual investors own about 5.08%.

The top shareholders of Syngene International include Biocon Limited, which holds the largest stake at 52.46%. Other significant shareholders are mutual funds, which collectively own 17.86% of the company, and foreign institutional investors (FIIs) who hold 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund, with a 5.13% stake. Additionally, individual investors own about 5.08% of the shares.

Who are in the management team of Syngene Intl.?

As of March 2022, the management team of Syngene International includes Kiran Mazumdar Shaw (Chairperson), Jonathan Hunt (Managing Director & CEO), and several independent directors, bringing diverse expertise to the company.

As of March 2022, the management team of Syngene International includes:<BR><BR>1. Kiran Mazumdar Shaw - Chairperson<BR>2. Catherine Patricia Rosenberg - Director<BR>3. Paul Frederick Blackburn - Independent Director<BR>4. Vijay Kuchroo - Independent Director<BR>5. Jonathan Hunt - Managing Director & CEO<BR>6. Vinita Bali - Lead Independent Director<BR>7. Priyadarshnini Mahapatra - Company Secretary & Compliance Officer<BR>8. Sharmila Karve - Independent Director<BR>9. Carl Decicco - Director<BR>10. Kush Parmar - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Syngene Intl. do?

Syngene International Limited is a large-cap integrated research, development, and manufacturing services organization in the healthcare sector, with recent net sales of ₹1,018 Cr and a net profit of ₹183 Cr for the quarter ending March 2025. The company has a market cap of ₹26,022 Cr and key metrics include a P/E ratio of 55.00 and a dividend yield of 0.19%.

Overview:<BR>Syngene International Limited is an integrated research, development, and manufacturing services organization operating in the healthcare services industry and classified as a large-cap company.<BR><BR>History:<BR>Syngene International was incorporated in an unspecified year and has maintained its status as a leading service provider in the healthcare sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,018 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 183 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 26,022 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.19% <BR>Debt-Equity: -0.17 <BR>Return on Equity: 9.99% <BR>Price-to-Book: 5.52 <BR><BR>Contact Details:<BR>Address: Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds Bengaluru Karnataka : 560099 <BR>Phone: 91-80-68915000/67758781 <BR>Email: investor@syngeneintl.com <BR>Website: http://www.syngeneintl.com

What is the bonus history of the Syngene Intl.?

Syngene International Ltd announced a 1:1 bonus issue on June 11, 2019, with a record date of June 12, 2019, allowing shareholders to receive one additional share for each share held.

Syngene International Ltd has a bonus history that includes a 1:1 bonus issue announced on June 11, 2019. The record date for this bonus was June 12, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Syngene Intl. declared dividend?

Syngene International Ltd has declared a dividend of 12% (₹1.2 per share) with an ex-date of June 28, 2024. While recent total returns have been negative, longer-term performance shows positive growth.

Syngene International Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -30.02%, the dividend return was 0.14%, resulting in a total return of -29.88%.<BR><BR>Over the past year, the price return was -5.96%, the dividend return was 0.34%, leading to a total return of -5.62%.<BR><BR>For the 2-year period, the price return was -12.31%, the dividend return was 0.42%, culminating in a total return of -11.89%.<BR><BR>In the last 3 years, the price return was 20.73%, the dividend return was 0.65%, resulting in a total return of 21.38%.<BR><BR>Over the past 4 years, the price return was 9.33%, the dividend return was 0.62%, leading to a total return of 9.95%.<BR><BR>In the 5-year period, the price return was 74.97%, the dividend return was 0.89%, culminating in a total return of 75.86%.<BR><BR>Overall, while Syngene International Ltd has declared a dividend, the total returns over various periods show a mixed performance, with significant declines in the short term but positive returns over the longer term.

Who are the peers of the Syngene Intl.?

Syngene Intl.'s peers include Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Health, Thyrocare Tech., Suven Life Sciences, Laxmi Dental, and Vimta Labs. Syngene has good management risk but below-average growth and the lowest 1-year return among its peers at -3.62%.

Peers: The peers of Syngene Intl. are Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Laxmi Dental, and Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Below Average management risk is noted at Suven Life Scie. and Average management risk is found at Krsnaa Diagnost. Growth is Good at Laxmi Dental, Average at Poly Medicure, Indegene, and Vimta Labs, while Below Average growth is observed at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest, with Suven Life Scie. showing Below Average growth. Excellent capital structure is seen at Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Good capital structure is noted at Laxmi Dental, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 160.99%, while the lowest is Syngene Intl. at -3.62%. Syngene Intl.'s 1-year return is lower than that of all its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Krsnaa Diagnost.

How big is Syngene Intl.?

As of 24th July, Syngene International Ltd has a market capitalization of 26,910.00 Cr, with recent net sales of 3,727.20 Cr and a net profit of 507.20 Cr.

As of 24th July, Syngene International Ltd has a market capitalization of 26,910.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Syngene reported Net Sales of 3,727.20 Cr and a Net Profit of 507.20 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4,726.80 Cr and Total Assets of 6,766.50 Cr.

How has been the historical performance of Syngene Intl.?

Syngene Intl. has shown consistent growth in net sales and operating profit from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025, although profit after tax slightly declined in 2025. Total assets and cash flow from operations have also improved significantly during this period.

Answer:<BR>The historical performance of Syngene Intl. shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Syngene Intl. has demonstrated a strong upward trend in net sales, increasing from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025. This growth is reflected in the total operating income, which also rose from INR 1,825.60 crore to INR 3,642.40 crore during the same period. The company's operating profit (PBDIT) has similarly improved, reaching INR 1,113.60 crore in March 2025, up from INR 611.90 crore in March 2019. However, profit after tax showed a slight decline from INR 510.00 crore in March 2024 to INR 496.20 crore in March 2025. The total assets of Syngene increased significantly from INR 4,040.20 crore in March 2020 to INR 6,766.50 crore in March 2025, while total liabilities also rose from INR 4,040.20 crore to INR 6,766.50 crore in the same timeframe. Cash flow from operating activities has improved, reaching INR 1,167.00 crore in March 2025, compared to INR 677.00 crore in March 2020, indicating a positive cash generation trend. Overall, Syngene Intl. has shown robust growth in revenue and operational efficiency, despite some fluctuations in net profit.

Is Syngene Intl. technically bullish or bearish?

As of December 4, 2025, Syngene Intl. shows a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearishness, despite some mildly bullish signals from the weekly MACD.

As of 4 December 2025, the technical trend for Syngene Intl. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the weekly OBV also showing mild bearishness. The MACD on the weekly chart is mildly bullish, but the monthly MACD remains bearish, suggesting mixed signals across time frames. The Bollinger Bands are bearish on both weekly and monthly charts, reinforcing the bearish sentiment. Overall, while there are some mildly bullish indicators, the prevailing trend remains bearish.

When is the next results date for Syngene International Ltd?

The next results date for Syngene International Ltd is April 29, 2026.

The next results date for Syngene International Ltd is scheduled for April 29, 2026.

Are Syngene International Ltd latest results good or bad?

Syngene International Ltd's latest results show strong revenue growth with Q4 FY26 net sales reaching ₹1,036.50 crores, but profitability is a concern as net profit declined 19.31% year-on-year despite a significant quarter-on-quarter increase. Investors should be cautious due to margin compression and ongoing operational challenges.

Syngene International Ltd's latest results present a mixed picture. On one hand, the company achieved its highest quarterly revenue in recent history, with net sales of ₹1,036.50 crores for Q4 FY26, reflecting a strong quarter-on-quarter growth of 13.02% and a modest year-on-year increase of 1.82%. This indicates a recovery in business momentum, likely driven by improved project execution and capacity utilization.<BR><BR>However, the profitability metrics raise concerns. While net profit surged by an impressive 886% quarter-on-quarter to ₹147.90 crores, it still represents a decline of 19.31% compared to the same quarter last year. Additionally, both operating margins and profit after tax margins saw significant contractions, indicating ongoing challenges with cost pressures and operational efficiency. The operating margin fell to 29.27%, down from 33.75% a year ago, and the PAT margin decreased to 14.27% from 18.01%.<BR><BR>Overall, while the revenue growth is a positive sign, the decline in profitability and margin compression suggests that the company is facing structural challenges that need to be addressed. Investors may want to approach with caution, considering both the strong revenue performance and the concerning trends in profitability.

Should I buy, sell or hold Syngene International Ltd?

Which are the latest news on Syngene Intl.?

Why is Syngene International Ltd falling/rising?

As of 24-May, Syngene International Ltd's stock price is declining, currently at Rs 461.75, with a significant annual return of -27.45%. The company's weak financial performance, high valuation, and decreased investor interest contribute to this downward trend.

As of 24-May, Syngene International Ltd's stock price is falling, currently at Rs 461.75, reflecting a decrease of Rs 8.5 or 1.81%. This decline is part of a broader trend, as the stock has underperformed against the benchmark indices, generating a return of -27.45% over the past year, compared to a -6.84% return for the Sensex. <BR><BR>The company's financial performance has shown signs of weakness, with net sales growing at an annual rate of only 11.35% and operating profit at a mere 3.22% over the last five years. Additionally, the latest six-month period reported a significant decline in profit after tax (PAT), which fell by 34.89%. The return on capital employed (ROCE) is at a low of 10.12%, and the return on equity (ROE) stands at 7.4%, indicating that the company is not generating sufficient returns relative to its equity.<BR><BR>Moreover, the stock's valuation appears expensive, trading at a price-to-book value of 3.9, which is higher than the average historical valuations of its peers. This premium valuation, combined with the consistent underperformance against the BSE500 over the last three years, has contributed to investor skepticism.<BR><BR>Investor participation has also declined, as evidenced by a significant drop in delivery volume, which fell by 61.29% against the five-day average. This lack of interest may further pressure the stock price. Overall, these factors collectively indicate why Syngene International Ltd's stock is currently experiencing a downward trend.